{
  "abstract": "The current treatment regimen for neuroblastoma involves immunotherapy, including a monoclonal antibody that recognizes disialoganglioside (GD2), expressed at high levels on neuroblastoma. GD2 is not present on most normal tissues except for nerves. Thus, anti-GD2 antibody treatment causes substantial, dose-limiting neuropathic pain. B7-H3 is overexpressed on multiple tumor types, including neuroblastoma, and is largely absent on nerves and other normal tissues. We designed a bispecific antibody (bsAb) that requires simultaneous binding of these two tumor antigens to achieve tight binding of tumor cells. Our preclinical research shows that, compared with a monospecific anti-GD2 antibody, the GD2xB7-H3 bsAb has improved tumor specificity, comparable antitumor efficacy, and reduced nerve binding and pain-associated toxicity. Since this bsAb does not bind to nerves, it may permit more tolerable and sustained treatment schedules than are currently feasible with monospecific anti-GD2 antibodies. In addition, its enhanced tumor specificity may support future development as a targeted delivery platform for antibody-drug conjugates or other payload-based therapies, potentially improving both efficacy and quality of life for patients with neuroblastoma.",
  "abstract_shown": true,
  "affiliations": [
    "University of Wisconsin-Madison"
  ],
  "article_type": "New results",
  "arxiv": null,
  "author_total": 30,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "A. Erbe"
    },
    {
      "name": "A. Feils"
    },
    {
      "name": "S. Reinthaler"
    },
    {
      "name": "A. Hampton"
    },
    {
      "name": "Z. Rosenkrans"
    },
    {
      "name": "Y. Medina Guevara"
    },
    {
      "name": "M. Felder"
    },
    {
      "name": "J. Wiwczar"
    },
    {
      "name": "D. Gerhardt"
    },
    {
      "name": "M. Bercher"
    },
    {
      "name": "B. Wenke"
    },
    {
      "name": "C. Haertle"
    },
    {
      "name": "M. Heck"
    },
    {
      "name": "K. Heimstreet"
    },
    {
      "name": "E. Frankel"
    },
    {
      "name": "M. Nielsen"
    },
    {
      "name": "D. Spiegelman"
    },
    {
      "name": "N. Tsarovsky"
    },
    {
      "name": "J. Zaborek"
    },
    {
      "name": "A. Rakhmilevich"
    },
    {
      "name": "J. Hank"
    },
    {
      "name": "E. Aluicio-Sarduy"
    },
    {
      "name": "J. Engle"
    },
    {
      "name": "J. Davis"
    },
    {
      "name": "B. Glaser"
    },
    {
      "name": "V. Subbotin"
    },
    {
      "name": "R. Green"
    },
    {
      "name": "R. Hernandez"
    },
    {
      "name": "B. Hammer"
    },
    {
      "name": "P. Sondel"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/88c0rpz7b2vwe.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.09.21.753180",
  "fulltext_url": "https://www.biorxiv.org/content/10.64898/2026.09.21.753180v1.full",
  "id": "88c0rpz7b2vwe",
  "issns": [],
  "landing_url": "https://www.biorxiv.org/content/10.64898/2026.09.21.753180v1",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "biorxiv",
      "cancer biology"
    ],
    [
      "openalex",
      "2728|Neuroblastoma Research and Treatments"
    ]
  ],
  "openalex": "W7214043723",
  "pdf_url": "https://www.biorxiv.org/content/10.64898/2026.09.21.753180v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-21",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/88c0rpz7b2vwe.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:23:51Z",
      "native_id": "10.64898/2026.09.21.753180",
      "source": "biorxiv",
      "url": "https://www.biorxiv.org/content/10.64898/2026.09.21.753180v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "biorxiv:cancer biology",
      "subfield": "oncology"
    }
  ],
  "title": "Bispecific GD2xB7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma",
  "title_text": "Bispecific GD2xB7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma",
  "type": "preprint",
  "updated_at": "2026-10-30T12:23:51Z",
  "url": "https://research.draconitic.com/paper/88c0rpz7b2vwe",
  "venue": "bioRxiv",
  "versions": []
}